TY - JOUR
T1 - CD140b and CD73 are markers for human induced pluripotent stem cell-derived erythropoietin-producing cells
AU - Nishimoto, Shogo
AU - Mizuno, Tomohiro
AU - Takahashi, Kazuo
AU - Nagano, Fumihiko
AU - Yuzawa, Yukio
AU - Nishiyama, Akira
AU - Osafune, Kenji
AU - Hitomi, Hirofumi
AU - Nagamatsu, Tadashi
N1 - Publisher Copyright:
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Renal anemia in chronic kidney disease is treated with recombinant human erythropoietin (rhEPO). However, some patients with anemia do not respond well to rhEPO, emphasizing the need for a more biocompatible EPO. Differentiation protocols for hepatic lineages have been modified to enable production from human induced pluripotent stem cell (hiPSC)-derived EPO-producing cells (EPO cells). However, markers for hiPSC-EPO cells are lacking, making it difficult to purify hiPSC-EPO cells and therefore to optimize EPO production and cell counts for transplantation. To address these issues, we investigated whether CD140b and CD73 could be used as markers for hiPSC-EPO cells. We measured the expression of EPO, CD140b, and CD73 in hiPSC-EPO cells and the EPO concentration in the cell supernatant by immunohistochemistry and enzyme-linked immunosorbent assays on culture day 13, revealing that expression levels of CD140b and CD73 are correlated with the level of EPO. In addition, rates of CD140b+ CD73+ cells were observed to be correlated with the concentration of EPO. Thus, our results suggest that CD140b and CD73 may be markers for hiPSC-EPO cells.
AB - Renal anemia in chronic kidney disease is treated with recombinant human erythropoietin (rhEPO). However, some patients with anemia do not respond well to rhEPO, emphasizing the need for a more biocompatible EPO. Differentiation protocols for hepatic lineages have been modified to enable production from human induced pluripotent stem cell (hiPSC)-derived EPO-producing cells (EPO cells). However, markers for hiPSC-EPO cells are lacking, making it difficult to purify hiPSC-EPO cells and therefore to optimize EPO production and cell counts for transplantation. To address these issues, we investigated whether CD140b and CD73 could be used as markers for hiPSC-EPO cells. We measured the expression of EPO, CD140b, and CD73 in hiPSC-EPO cells and the EPO concentration in the cell supernatant by immunohistochemistry and enzyme-linked immunosorbent assays on culture day 13, revealing that expression levels of CD140b and CD73 are correlated with the level of EPO. In addition, rates of CD140b+ CD73+ cells were observed to be correlated with the concentration of EPO. Thus, our results suggest that CD140b and CD73 may be markers for hiPSC-EPO cells.
KW - CD140b
KW - CD73
KW - chronic kidney disease
KW - erythropoietin
KW - human induced pluripotent stem cells
UR - http://www.scopus.com/inward/record.url?scp=85079716834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079716834&partnerID=8YFLogxK
U2 - 10.1002/2211-5463.12800
DO - 10.1002/2211-5463.12800
M3 - Article
C2 - 31977161
AN - SCOPUS:85079716834
SN - 2211-5463
VL - 10
SP - 427
EP - 433
JO - FEBS Open Bio
JF - FEBS Open Bio
IS - 3
ER -
